Drotrecogin Alfa (Activated) in Adults with Septic Shock

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F12%3A43907127" target="_blank" >RIV/00064173:_____/12:43907127 - isvavai.cz</a>
Alternative codes found
RIV/00064173:_____/12:N0000008
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1202290" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1202290</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1202290" target="_blank" >10.1056/NEJMoa1202290</a>

Result language
angličtina
Original language name
Drotrecogin Alfa (Activated) in Adults with Septic Shock
Original language description
There have been conflicting reports on the efficacy of recombinant human activated protein C, or drotrecogin alfa (activated) (DrotAA), for the treatment of patients with septic shock. METHODS In this randomized, double-blind, placebo-controlled, multicenter trial, we assigned 1697 patients with infection, systemic inflammation, and shock who were receiving fluids and vasopressors above a threshold dose for 4 hours to receive either DrotAA (at a dose of 24 mu g per kilogram of body weight per hour) or placebo for 96 hours. The primary outcome was death from any cause 28 days after randomization. RESULTS At 28 days, 223 of 846 patients (26.4%) in the DrotAA group and 202 of 834 (24.2%) in the placebo group had died (relative risk in the DrotAA group, 1.09; 95% confidence interval [CI], 0.92 to 1.28; P = 0.31). At 90 days, 287 of 842 patients (34.1%) in the DrotAA group and 269 of 822 (32.7%) in the placebo group had died (relative risk, 1.04; 95% CI, 0.90 to 1.19; P = 0.56). Among patie
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FI - Traumatology and orthopaedics
OECD FORD branch
—

Publication year
2012
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)